Las acciones de Moderna subieron pronunciadamente el miércoles después de que anunciara resultados iniciales de un estudio sobre un tratamiento experimental contra el cáncer que, de ser aprobado, ...
The study also met a secondary goal of preventing cancer from spreading to different parts of the body.
Moderna shares shot up after the company announced initial results from a study of an experimental mRNA-based cancer vaccine ...
The Treasury Department said it will more than double the size of its debt buybacks, sending Treasury yields lower.
Moderna and Merck said their personalized cancer treatment showed positive results in their first-ever late-stage trial. Here ...
Moderna is up 130% today with success of a phase 3 trial on AI Assisted personalized MRNA cancer treatment. This is freaking ...
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...
The main U.S. stock indexes recovered on Wednesday after a technology-driven slump in the previous session as government bond ...
A mRNA cancer vaccine showed positive results in a late-stage melanoma trial, Moderna and Merck announced Wednesday.
The Phase 3 results build on earlier Phase 2b findings and showed that the combination of intismeran and Keytruda reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results